Presence of PTSD and Emotion Dysregulation Among Inpatients With Substance Use Disorder
Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Apr 2, 2024
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the connection between Post Traumatic Stress Disorder (PTSD) and Substance Use Disorder (SUD) in patients receiving treatment. Many people with SUD also have PTSD, but often they don’t receive the help they need for both conditions at the same time. The researchers want to see if combining two types of therapy—Dialectical Behavior Therapy (DBT), which helps with managing emotions, and Narrative Exposure Therapy (NET), which focuses on healing from trauma—can improve treatment outcomes for patients. They will look at things like the severity of PTSD symptoms, the rate of self-harm, and the likelihood of patients dropping out of treatment or relapsing after leaving the program.
To be eligible for the study, participants should be between 18 and 74 years old, speak a Scandinavian language (like Norwegian, Danish, or Swedish), and be willing to participate. They should also have experienced a traumatic event that meets certain criteria and have difficulty regulating their emotions. During the trial, participants will receive standard treatment for SUD along with the new therapies, and the researchers will check in with them after treatment and again at 3 and 12 months to see how they are doing. This study aims to help improve treatment options for those dealing with both PTSD and substance use issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * General inclusion criteria for the study:
- • 1. Fit general inclusion criteria for the in-patient program.
- • 2. Speak Scandinavian (Norwegian, Danish and/or Swedish).
- • 3. Be willing to sign a consent.
- Inclusion criteria for NET intervention:
- • 1. Experience of an aversive event that fits criteria A for PTSD as defined by Diagnostic and Statistical Manual of Mental Disorders-V (DSM-V) (American Psychiatric Association \[APA\], 2013).
- • 2. Experience symptoms of PTSD as defined by the DSM-V (APA, 2013), or subthreshold PTSD (Grubaugh et al., 2005), or experience clinically relevant symptoms as evaluated by a NET therapist.
- • 1. Subthreshold PTSD is defined as having experienced a traumatic event (Criteria A), meeting Criteria B (re-experiencing symptoms), Criteria E (one-month symptom duration), and Criteria F (significant distress or functioning impairment) and either Criteria C (avoidance or numbing symptoms) or Criteria D (hyper arousal symptoms).
- Inclusion criteria for DBT intervention:
- • 1. Experience difficulties in emotion regulation evaluated by an assigned DBT therapist.
- • 2. Manage to commit to participating in the DBT- skills training.
- Exclusion Criteria:
- * General exclusion criteria for the study:
- • 1. Have a clinically significant low cognitive- and/or linguistic functioning that hinders the patient in understanding and answering the questions on the self-rapport instruments.
- • Exclusion criteria for NET and/or DBT-SUD skills
- • 1. Being actively psychotic.
- • 2. Have a Body Mass Index (BMI) under 17.
- • 3. Severe dissociation.
- • 4. An ongoing traumatic contact with the perpetrator.
About Norwegian University Of Science And Technology
The Norwegian University of Science and Technology (NTNU) is a leading research institution dedicated to advancing knowledge and innovation in various scientific fields. Renowned for its commitment to interdisciplinary collaboration, NTNU plays a pivotal role in addressing global health challenges through rigorous clinical trials and research initiatives. The university's emphasis on cutting-edge technology and its strong partnerships with healthcare sectors position it as a key player in translational research, ensuring that findings contribute effectively to improving public health and patient care. With a focus on ethical standards and scientific integrity, NTNU is dedicated to fostering advancements that enhance the quality of life and health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Molde, Møre And Romsdal, Norway
Molde, Norway
Patients applied
Trial Officials
Egil Jonsbu
Study Director
Norwegian University of Science and Technology
Johanna Vigfusdottir
Principal Investigator
Norwegian University of Science and Technology
Edvard Breivik
Principal Investigator
Norwegian University of Science and Technology
Erlend Mork
Study Chair
Oslo University Hospital
Lars Lien
Study Chair
National Competence Center for Co-Occurring Addictive and Psychiatric Disorders
Håkon Stenmark
Study Chair
Regional Center for Violence and Traumatic Stress and St. Olavs Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported